These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 34692599)

  • 1. Invasive Pneumococcal Disease in Latvia in PCV10 Vaccination Era, 2012-2018.
    Savrasova L; Krumina A; Cupeca H; Zeltina I; Villerusha A; Grope I; Viksna L; Dimina E; Balasegaram S
    Front Pediatr; 2021; 9():532489. PubMed ID: 34692599
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term impact of 10-valent pneumococcal conjugate vaccination on invasive pneumococcal disease among children in Finland.
    Rinta-Kokko H; Palmu AA; Auranen K; Nuorti JP; Toropainen M; Siira L; Virtanen MJ; Nohynek H; Jokinen J
    Vaccine; 2018 Apr; 36(15):1934-1940. PubMed ID: 29526371
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact and effectiveness of the 10-valent pneumococcal conjugate vaccine on invasive pneumococcal disease among children under 5 years of age in the Netherlands.
    Peckeu L; van der Ende A; de Melker HE; Sanders EAM; Knol MJ
    Vaccine; 2021 Jan; 39(2):431-437. PubMed ID: 33243632
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prompt effect of replacing the 7-valent pneumococcal conjugate vaccine with the 13-valent vaccine on the epidemiology of invasive pneumococcal disease in Norway.
    Steens A; Bergsaker MA; Aaberge IS; Rønning K; Vestrheim DF
    Vaccine; 2013 Dec; 31(52):6232-8. PubMed ID: 24176490
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term population impact of infant 10-valent pneumococcal conjugate vaccination on invasive pneumococcal disease in adults in Finland.
    Nuorti JP; Rinta-Kokko H; Toropainen M; Siira L; Nohynek H; Palmu AA
    Vaccine; 2022 Sep; 40(41):5950-5958. PubMed ID: 36075797
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Distribution of invasive Streptococcus pneumoniae serotypes before and 5 years after the introduction of 10-valent pneumococcal conjugate vaccine in Brazil.
    Brandileone MC; Almeida SCG; Minamisava R; Andrade AL
    Vaccine; 2018 May; 36(19):2559-2566. PubMed ID: 29650385
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pneumococcal carriage and invasive disease in children before introduction of the 13-valent conjugate vaccine: comparison with the era before 7-valent conjugate vaccine.
    Sharma D; Baughman W; Holst A; Thomas S; Jackson D; da Gloria Carvalho M; Beall B; Satola S; Jerris R; Jain S; Farley MM; Nuorti JP
    Pediatr Infect Dis J; 2013 Feb; 32(2):e45-53. PubMed ID: 23080290
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term Impact of a "3 + 0" Schedule for 7- and 13-Valent Pneumococcal Conjugate Vaccines on Invasive Pneumococcal Disease in Australia, 2002-2014.
    Jayasinghe S; Menzies R; Chiu C; Toms C; Blyth CC; Krause V; McIntyre P
    Clin Infect Dis; 2017 Jan; 64(2):175-183. PubMed ID: 27986682
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Invasive pneumococcal diseases in children and adults before and after introduction of the 10-valent pneumococcal conjugate vaccine into the Austrian national immunization program.
    Richter L; Schmid D; Kanitz EE; Zwazl I; Pöllabauer E; Jasinska J; Burgmann H; Kundi M; Wiedermann U
    PLoS One; 2019; 14(1):e0210081. PubMed ID: 30629620
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effectiveness of the seven-valent and thirteen-valent pneumococcal conjugate vaccines in England: The indirect cohort design, 2006-2018.
    Andrews N; Kent A; Amin-Chowdhury Z; Sheppard C; Fry N; Ramsay M; Ladhani SN
    Vaccine; 2019 Jul; 37(32):4491-4498. PubMed ID: 31272872
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of pneumococcal conjugate vaccine on invasive pneumococcal disease in children under 5 years of age in the Czech Republic.
    Kozakova J; Krizova P; Maly M
    PLoS One; 2021; 16(2):e0247862. PubMed ID: 33635933
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pneumococcal serotype evolution in Western Europe.
    Tin Tin Htar M; Christopoulou D; Schmitt HJ
    BMC Infect Dis; 2015 Oct; 15():419. PubMed ID: 26468008
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The impact of the changing pneumococcal national immunisation program among older Australians.
    Menzies R; Stein AN; Booy R; Van Buynder PG; Litt J; Cripps AW
    Vaccine; 2021 Jan; 39(4):720-728. PubMed ID: 33384189
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pneumococcal conjugate vaccine herd effects on non-invasive pneumococcal pneumonia in elderly.
    van Werkhoven CH; Hollingsworth RC; Huijts SM; Bolkenbaas M; Webber C; Patterson S; Sanders EA; Bonten MJ
    Vaccine; 2016 Jun; 34(28):3275-82. PubMed ID: 27171754
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Incidence of invasive pneumococcal disease before and during an era of use of three different pneumococcal conjugate vaccines in Quebec.
    De Wals P; Lefebvre B; Deceuninck G; Longtin J
    Vaccine; 2018 Jan; 36(3):421-426. PubMed ID: 29224962
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dynamic changes in paediatric invasive pneumococcal disease after sequential switches of conjugate vaccine in Belgium: a national retrospective observational study.
    Desmet S; Lagrou K; Wyndham-Thomas C; Braeye T; Verhaegen J; Maes P; Fieuws S; Peetermans WE; Blumental S
    Lancet Infect Dis; 2021 Jan; 21(1):127-136. PubMed ID: 32702303
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of childhood pneumococcal conjugate vaccination on invasive disease in older adults of 10 European countries: implications for adult vaccination.
    Hanquet G; Krizova P; Valentiner-Branth P; Ladhani SN; Nuorti JP; Lepoutre A; Mereckiene J; Knol M; Winje BA; Ciruela P; Ordobas M; Guevara M; McDonald E; Morfeldt E; Kozakova J; Slotved HC; Fry NK; Rinta-Kokko H; Varon E; Corcoran M; van der Ende A; Vestrheim DF; Munoz-Almagro C; Latasa P; Castilla J; Smith A; Henriques-Normark B; Whittaker R; Pastore Celentano L; Savulescu C;
    Thorax; 2019 May; 74(5):473-482. PubMed ID: 30355641
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Twelve years of pneumococcal conjugate vaccination in the Netherlands: Impact on incidence and clinical outcomes of invasive pneumococcal disease.
    Vestjens SMT; Sanders EAM; Vlaminckx BJ; de Melker HE; van der Ende A; Knol MJ
    Vaccine; 2019 Oct; 37(43):6558-6565. PubMed ID: 31500963
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Divergent serotype replacement trends and increasing diversity in pneumococcal disease in high income settings reduce the benefit of expanding vaccine valency.
    Løchen A; Croucher NJ; Anderson RM
    Sci Rep; 2020 Nov; 10(1):18977. PubMed ID: 33149149
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Serotype epidemiology of invasive pneumococcal disease in Swiss adults: a nationwide population-based study.
    Meichtry J; Born R; Küffer M; Zwahlen M; Albrich WC; Brugger SD; Mühlemann K; Hilty M
    Vaccine; 2014 Sep; 32(40):5185-91. PubMed ID: 25077419
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.